Our case illustrates several considerations that are made for long-term surviving patients with ALK-positive lung cancer during their late lines of treatment and provides additional support that IT therapy is worth evaluating in LM trials that include both oncogene-driven and non-oncogene driven lung cancers. This evidence concerns the gene ALK and lung cancer.